BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 34843402)

  • 1.
    Pan M; Jiang C; Tse P; Achacoso N; Alexeeff S; Solorzano AV; Chung E; Hu W; Truong TG; Arora A; Sundaresan T; Suga JM; Thomas S; Habel LA
    J Clin Oncol; 2022 Jan; 40(2):171-179. PubMed ID: 34843402
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Pan M; Jiang C; Zhang Z; Achacoso N; Alexeeff S; Solorzano AV; Tse P; Chung E; Sundaresan T; Suga JM; Thomas S; Habel LA
    JCO Precis Oncol; 2023 May; 7():e2200570. PubMed ID: 37163715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
    Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
    BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.
    Schulz-Heddergott R; Stark N; Edmunds SJ; Li J; Conradi LC; Bohnenberger H; Ceteci F; Greten FR; Dobbelstein M; Moll UM
    Cancer Cell; 2018 Aug; 34(2):298-314.e7. PubMed ID: 30107178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.
    Chapman L; Ledet EM; Barata PC; Cotogno P; Manogue C; Moses M; Christensen BR; Steinwald P; Ranasinghe L; Layton JL; Lewis BE; Sartor O
    Clin Genitourin Cancer; 2020 Apr; 18(2):148-154. PubMed ID: 31822380
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
    World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations.
    Chen J; Chang X; Li X; Liu J; Wang N; Wu Y; Zheng L; Nie X
    Cancer Med; 2023 Dec; 12(24):21920-21932. PubMed ID: 38063316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
    Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E;
    Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.
    Kang HJ; Chun SM; Kim KR; Sohn I; Sung CO
    PLoS One; 2013; 8(8):e72609. PubMed ID: 23967324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.
    Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C
    World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coaltered
    Datta J; Smith JJ; Chatila WK; McAuliffe JC; Kandoth C; Vakiani E; Frankel TL; Ganesh K; Wasserman I; Lipsyc-Sharf M; Guillem J; Nash GM; Paty PB; Weiser MR; Saltz LB; Berger MF; Jarnagin WR; Balachandran V; Kingham TP; Kemeny NE; Cercek A; Garcia-Aguilar J; Taylor BS; Viale A; Yaeger R; Solit DB; Schultz N; D'Angelica MI
    Clin Cancer Res; 2020 Mar; 26(5):1077-1085. PubMed ID: 31719050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 Gain-of-Function Mutation is a Poor Prognostic Factor in High-Methylated Metastatic Colorectal Cancer.
    Wakayama S; Ouchi K; Takahashi S; Yamada Y; Komatsu Y; Shimada K; Yamaguchi T; Shirota H; Takahashi M; Ishioka C
    Clin Colorectal Cancer; 2023 Sep; 22(3):327-338. PubMed ID: 37355363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of primary tumor sidedness on survival in early-onset colorectal cancer by stage: A National Veterans Affairs retrospective analysis.
    Azar I; Al Masalmeh N; Esfandiarifard S; Virk G; Kiwan W; Frank Shields A; Mehdi S; Philip PA
    Cancer Med; 2021 May; 10(9):2987-2995. PubMed ID: 33797856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gain-of-function mutant p53 in cancer progression and therapy.
    Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
    J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells.
    Klemke L; Fehlau CF; Winkler N; Toboll F; Singh SK; Moll UM; Schulz-Heddergott R
    Front Oncol; 2021; 11():642603. PubMed ID: 34178628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex- and Co-Mutation-Dependent Prognosis in Patients with SMARCA4-Mutated Malignancies.
    Pan M; Jiang C; Zhang Z; Achacoso N; Solorzano-Pinto AV; Tse P; Chung E; Suga JM; Thomas S; Habel LA
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.
    Yue X; Wu F; Li Y; Liu J; Boateng M; Mandava K; Zhang C; Feng Z; Gao J; Hu W
    Cell Cycle; 2020 Jun; 19(11):1338-1351. PubMed ID: 32275841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial.
    Stahler A; Stintzing S; von Einem JC; Westphalen CB; Heinrich K; Krämer N; Michl M; Modest DP; von Weikersthal LF; Decker T; Kiani A; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Kaiser F; Kirchner T; Jung A; Heinemann V
    Eur J Cancer; 2020 Sep; 137():250-259. PubMed ID: 32810748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics.
    Khan M; Loree JM; Advani SM; Ning J; Li W; Pereira AAL; Lam M; Raghav K; Morris VK; Broaddus R; Maru D; Overman MJ; Kopetz S
    Clin Colorectal Cancer; 2018 Dec; 17(4):e699-e709. PubMed ID: 30205948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.